Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Hanns Lochmüller

Showing results (1-10 of 489) with videos related to

Pageof 49
Sort By:
Drug News & Perspectives|October 11, 2007
Current status of gene therapy for muscle diseasesChristian Thirion, Hanns Lochmüller
Advances in Experimental Medicine and Biology|September 9, 2010
Biobanking in rare disordersHanns Lochmüller, Peter Schneiderat
Journal of Neurology|September 21, 2010
Neuromuscular disorders and 2010: recent advancesAnna Sarkozy, Hanns Lochmüller
Brain : a Journal of Neurology|September 2, 2025
Variant-specific deep phenotyping as a tool to develop precision therapiesRita Horvath, Hanns Lochmüller
Handbook of Clinical Neurology|April 19, 2011
SarcoglycanopathiesJanbernd Kirschner, Hanns Lochmüller
Neurotherapeutics : the Journal of the American Society for Experimental Neurotherapeutics|November 21, 2008
Therapeutic strategies in congenital myasthenic syndromesUlrike Schara, Hanns Lochmüller
Neurology|December 11, 2002
What's in the serum of seronegative MG and LEMS?: MuSK et alAngela Abicht, Hanns Lochmüller
Journal of Neurology, Neurosurgery, and Psychiatry|May 23, 2013
Becker and Duchenne muscular dystrophy: a two-way information process for therapiesHanns Lochmüller, Kate Bushby
Neurology|May 31, 2007
What message does the nuclear envelope hold?Hanns Lochmüller, Manfred Wehnert
Neurology|June 6, 2008
Sarcoglycans take center stage in gene transfer therapyOliver J Müller, Hanns Lochmüller
Pageof 49

Showing results (1-10 of 489) with videos related to

Sort By:
Pageof 49
Drug News & Perspectives|October 11, 2007
Current status of gene therapy for muscle diseasesChristian Thirion, Hanns Lochmüller
Advances in Experimental Medicine and Biology|September 9, 2010
Biobanking in rare disordersHanns Lochmüller, Peter Schneiderat
Journal of Neurology|September 21, 2010
Neuromuscular disorders and 2010: recent advancesAnna Sarkozy, Hanns Lochmüller
Brain : a Journal of Neurology|September 2, 2025
Variant-specific deep phenotyping as a tool to develop precision therapiesRita Horvath, Hanns Lochmüller
Handbook of Clinical Neurology|April 19, 2011
SarcoglycanopathiesJanbernd Kirschner, Hanns Lochmüller
Neurotherapeutics : the Journal of the American Society for Experimental Neurotherapeutics|November 21, 2008
Therapeutic strategies in congenital myasthenic syndromesUlrike Schara, Hanns Lochmüller
Neurology|December 11, 2002
What's in the serum of seronegative MG and LEMS?: MuSK et alAngela Abicht, Hanns Lochmüller
Journal of Neurology, Neurosurgery, and Psychiatry|May 23, 2013
Becker and Duchenne muscular dystrophy: a two-way information process for therapiesHanns Lochmüller, Kate Bushby
Neurology|May 31, 2007
What message does the nuclear envelope hold?Hanns Lochmüller, Manfred Wehnert
Neurology|June 6, 2008
Sarcoglycans take center stage in gene transfer therapyOliver J Müller, Hanns Lochmüller
Pageof 49